Immunic, Inc.

NasdaqCM:IMUX 주식 리포트

시가총액: US$200.1m

Immunic 경영진

경영진 기준 점검 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Erik Lundgren

최고경영자

n/a

총 보수

CEO 급여 비율n/a
CEO 재임 기간less than a year
CEO 지분 보유율n/a
경영진 평균 재임 기간3.4yrs
이사회 평균 재임 기간5.7yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
분석 기사 • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
분석 기사 • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO

Erik Lundgren (48 yo)

less than a year
재임 기간

Mr. Erik Lundgren is Chief Executive Officer of Immunic, Inc. from June 1, 2026 and also serves as Director from 2026. Mr. Lundgren served as Senior Vice President, Commercial Portfolio Organization at Gen...

리더십 팀

이름직위재임 기간보수지분
Jason Tardio
COO & President2yrsUS$1.20m0.0092%
$ 18.4k
Daniel Vitt
Co-Founder & Directorno dataUS$2.30m0.29%
$ 575.7k
Glenn Whaley
Chief Financial Officer6.3yrsUS$1.06m0.070%
$ 140.3k
Erik Lundgren
CEO & Directorless than a year데이터 없음데이터 없음
Hella Kohlhof
Co-Founder & Chief Scientific Officer9.5yrs데이터 없음데이터 없음
Jessica Breu
Vice President of Investor Relations & Communicationsno data데이터 없음데이터 없음
Inderpal Singh
General Counsel5.1yrs데이터 없음데이터 없음
Patrick Walsh
Chief Business Officer4.8yrs데이터 없음데이터 없음
Werner Gladdines
Chief Development Officer2yrs데이터 없음데이터 없음
Michael A. Panzara
Chief Medical Officerless than a year데이터 없음데이터 없음
3.4yrs
평균 재임 기간
53yo
평균 나이

경험이 풍부한 관리: IMUX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.4 년).

이사회 구성원

이름직위재임 기간보수지분
Daniel Vitt
Co-Founder & Director7.3yrsUS$2.30m0.29%
$ 575.7k
Erik Lundgren
CEO & Directorless than a year데이터 없음데이터 없음
Barclay Phillips
Lead Independent Director6.7yrsUS$171.98k0.21%
$ 412.7k
Michael Bonney
Chair of the Boardless than a year데이터 없음데이터 없음
Jorg Neermann
Independent Director7.3yrsUS$156.98k0.15%
$ 293.8k
Paul Utz
Member of Scientific Medical Advisory Board5.7yrs데이터 없음데이터 없음
Duane Nash
Director7.5yrsUS$979.88k0.026%
$ 52.9k
Bruce Sands
Member of Scientific Medical Advisory Board5.7yrs데이터 없음데이터 없음
Fred Lublin
Member of Scientific Medical Advisory Board5.7yrs데이터 없음데이터 없음
Richard Rudick
Independent Director3.3yrsUS$149.48k0.17%
$ 338.4k
Jon Congleton
Independent Directorless than a year데이터 없음데이터 없음
Simona Skerjanec
Independent Director2yrsUS$149.14k0.15%
$ 293.8k
5.7yrs
평균 재임 기간
61yo
평균 나이

경험이 풍부한 이사회: IMUX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.7 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/15 22:25
종가2026/07/15 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Immunic, Inc.는 18명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets